Paeds · fetal-neonatal-and-perinatal
Neonatal abstinence and withdrawal syndromes
Also known as Neonatal abstinence syndrome · Neonatal opioid withdrawal syndrome · NOWS · Neonatal drug withdrawal
Fellowship guide to neonatal abstinence and withdrawal syndromes: how chronic in-utero opioid exposure reprograms fetal neurotransmitter circuits so that cord clamping unleashes a hyperadrenergic withdrawal, the Finnegan and Eat Sleep Console assessment paradigms, the non-pharmacologic first-line bundle of rooming-in and breastfeeding, and the pharmacologic ladder from morphine to buprenorphine.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Withdrawal seizures — a late, severe sign demanding urgent pharmacotherapy and exclusion of hypoglycaemia, hypocalcaemia and sepsis
- An opioid-exposed infant who cannot eat, sleep or be consoled despite maximal non-pharmacologic care
- Finnegan score of three consecutive scores of 8 or more (or two consecutive scores of 12 or more)
- Failure to thrive from feeding failure and vomiting despite maximal conservative management
- Unidentified polysubstance exposure — alcohol, benzodiazepines or gabapentin — which deepens and prolongs withdrawal
Life stages
Care settings
Clinical exam formats
Board mappings
- Neonatal medicine and immediate newborn care
- Recognition and management of neonatal opioid withdrawal syndrome
- Maternal substance use and its effect on the newborn
- Pharmacologic and non-pharmacologic management of neonatal abstinence syndrome
- Eat Sleep Console and Finnegan-based assessment paradigms
- Multidisciplinary discharge planning and plans of safe care
- Neurobiology of opioid withdrawal: receptor adaptation and the noradrenergic surge
- Assessment tools: Finnegan NASS, Lipsitz, and the functional Eat Sleep Console approach
- Pharmacotherapy: morphine versus buprenorphine and weaning strategy
- Long case: the opioid-exposed newborn with evolving withdrawal
- Communication: counselling a mother with opioid use disorder on breastfeeding and rooming-in
- Neonatology: neonatal abstinence syndrome and neonatal opioid withdrawal syndrome
- Patient management: non-pharmacologic care and pharmacologic escalation
- Patient investigation: exclusion of mimics and co-morbid conditions
- Neonatal physiology: opioid receptor adaptation and the withdrawal cascade
- Assessment scoring systems and treatment thresholds
- Evidence base: buprenorphine RCT, ESC outcomes, breastfeeding and rooming-in
- Neonatal abstinence syndrome management station
- Communication: supporting a mother with opioid use disorder
- Neonatal opioid withdrawal syndrome: assessment, non-pharmacologic care, and pharmacotherapy
- Maternal opioid use disorder and the neonatal impact
- Discharge planning, follow-up and plans of safe care
- Patient Care: management of neonatal opioid withdrawal syndrome
- Medical Knowledge: neurobiology of opioid dependence and withdrawal
- Systems-Based Practice: maternal–infant dyad care, child protection and follow-up
- Medical Expert: neonatal abstinence and withdrawal syndromes
- Health Advocate: harm reduction, breastfeeding access and social support
- Collaborator: maternal addiction services, lactation and child protection
Overview & Definition
A 36-week infant whose mother is on a methadone maintenance programme is admitted to the postnatal ward at 48 hours of age with a high-pitched cry, tremor when handled, and poor feeding. This is the archetypal presentation, and the question is not whether this is withdrawal — it almost certainly is — but how severe it is and whether it needs a drug. Neonatal abstinence syndrome is the clinical syndrome of postnatal withdrawal that follows chronic in-utero exposure to a substance on which the fetus has become physically dependent; when the exposure is an opioid, the term neonatal opioid withdrawal syndrome (NOWS) is used more precisely. [3]
The defining idea is neuroadaptation. Opioids cross the placenta freely, and over weeks of exposure the fetal brain adjusts its receptor density and neurotransmitter tone to maintain equilibrium in the presence of the drug. The opioid itself suppresses the locus coeruleus, the brain's noradrenaline engine, so the fetus compensates by up-regulating noradrenergic and dopaminergic pathways. At birth, the cord is clamped and the opioid supply stops abruptly, but the compensatory up-regulation persists — and the result is an unopposed surge of CNS and autonomic activity that we call withdrawal. [3] [5]
Three facts frame the topic for fellowship. First, it is common and rising — Patrick and colleagues showed that NAS incidence in the United States roughly tripled across the first decade of the 2000s, and it remains a leading driver of neonatal length of stay. [4] Second, it is largely manageable without drugs — a bundled approach of rooming-in, breastfeeding and functional assessment now allows most exposed infants to avoid pharmacotherapy altogether. [7] [9] Third, the harm extends beyond the neonatal stay — maternal opioid use disorder is associated with an elevated risk of postneonatal infant mortality, which is why discharge planning and follow-up are part of treatment, not an afterthought. [12]
References12ShowHide
- [1]Finnegan LP Neonatal abstinence syndrome: assessment and management. Addict Dis, 1975.PMID 1163358
- [2]Lipsitz PJ A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. Clin Pediatr (Phila), 1975.PMID 1126108
- [3]Hudak ML Neonatal drug withdrawal. Pediatrics, 2012.PMID 22291123
- [4]Patrick SW Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA, 2012.PMID 22546608
- [5]Jones HE Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med, 2010.PMID 21142534
- [6]Kraft WK Buprenorphine for the Neonatal Abstinence Syndrome. N Engl J Med, 2017.PMID 28877016
- [7]Grossman MR Neonatal Abstinence Syndrome: Time for a Reappraisal. Hosp Pediatr, 2017.PMID 28137921
- [8]Blount T Reduction in Length of Stay and Morphine Use for NAS With the Eat, Sleep, Console Method. Hosp Pediatr, 2019.PMID 31285356
- [9]Welle-Strand GK Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. Acta Paediatr, 2013.PMID 23909865
- [10]Holmes AP Breastfeeding Considerations for Mothers of Infants with Neonatal Abstinence Syndrome. Pharmacotherapy, 2017.PMID 28488805
- [11]Patrick SW Association Among County-Level Economic Factors, Clinician Supply, Metropolitan or Rural Location, and Neonatal Abstinence Syndrome. JAMA, 2019.PMID 30694320
- [12]Grossarth S Maternal Opioid Use Disorder and the Risk of Postneonatal Infant Mortality. JAMA Pediatr, 2023.PMID 37155175